Canada - English - Health Canada

pfizer canada ulc - alprostadil; water - kit - 11.9mcg; 99.1% - alprostadil 11.9mcg; water 99.1% - miscellaneous vasodilatating agents

Canada - English - Health Canada

pfizer canada ulc - alprostadil - kit - 20mcg - alprostadil 20mcg - miscellaneous vasodilatating agents

Canada - English - Health Canada

pfizer canada ulc - alprostadil - powder for solution - 20mcg - alprostadil 20mcg - miscellaneous vasodilatating agents

Canada - English - Health Canada

paladin labs inc. - alprostadil - suppository - 125mcg - alprostadil 125mcg - miscellaneous vasodilatating agents

Canada - English - Health Canada

paladin labs inc. - alprostadil - suppository - 250mcg - alprostadil 250mcg - miscellaneous vasodilatating agents

Canada - English - Health Canada

paladin labs inc. - alprostadil - suppository - 500mcg - alprostadil 500mcg - miscellaneous vasodilatating agents

Canada - English - Health Canada

paladin labs inc. - alprostadil - suppository - 1000mcg - alprostadil 1000mcg - miscellaneous vasodilatating agents

Canada - English - Health Canada

pfizer canada ulc - alprostadil - solution - 500mcg - alprostadil 500mcg - miscellaneous vasodilatating agents

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - alprostadil, quantity: 500 microgram/ml - injection, solution - excipient ingredients: ethanol - indications as at 14 january 1994: prostin vr sterile solution (alprostadil) is indicated for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon a patent ductus for survival. such congenital heart defects include pulmonary atresia, pulmonary stenosis, tricuspid atresia, tetralogy of fallot, interruption of the aortic arch, coarctation of the aorta, mitral atresia, or transposition of the great vessels with or without other defects. prostin vr should be administered only by medically trained personnel in facilities in which paediatric patients can receive or have access to paediatric intensive care.

United States - English - NLM (National Library of Medicine)

pharmacia & upjohn company llc - alprostadil (unii: f5td010360) (alprostadil - unii:f5td010360) - prostin vr pediatric sterile solution is indicated for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. such congenital heart defects include pulmonary atresia, pulmonary stenosis, tricuspid atresia, tetralogy of fallot, interruption of the aortic arch, coarctation of the aorta, or transposition of the great vessels with or without other defects. in infants with restricted pulmonary blood flow, the increase in blood oxygenation is inversely proportional to pretreatment po2 values; that is, patients with low po2 values respond best, and patients with po2 values of 40 torr or more usually have little response. prostin vr pediatric should be administered only by trained personnel in facilities that provide pediatric intensive care. none.